Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda symbols : NVO save search
FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight
Published: 2024-03-08 (Crawled : 20:00) - prnewswire.com
NVO | $123.58 -0.26% 2.2M
|
Health Technology
| Email alert
Add to watchlist
fda obesity first treatment risk heart
FDA approves Rivfloza™ for children ≥9 years old and adults living with primary hyperoxaluria type 1 (PH1), a rare genetic condition
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: -0.85%
H: 3.13%
C: 1.81%
fda rare children genetic living
Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism
Published: 2023-08-30 (Crawled : 06:00) - globenewswire.com
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: -0.72%
H: 0.36%
C: -0.49%
fda pharma review designation
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
Published: 2023-06-30 (Crawled : 18:00) - globenewswire.com
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 2.23%
H: 0.97%
C: 0.81%
fda pharma drug application
Beta Bionics Announces FDA Clearance for the Use of a Prefilled Insulin Cartridge With the iLet Bionic Pancreas
Published: 2023-06-22 (Crawled : 14:00) - biospace.com/
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: -0.45%
H: 0.89%
C: 0.13%
fda pancreas clearance insulin
Novo Nordisk announces FDA approval of label update for Rybelsus® (semaglutide) allowing use as a first-line option for adults with type 2 diabetes
Published: 2023-01-13 (Crawled : 02:00) - prnewswire.com
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 1.51%
H: 0.89%
C: 0.5%
rybelsus fda label approval diabetes update
Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors
Published: 2022-08-17 (Crawled : 12:20) - globenewswire.com
IXHL | $2.66 0.38% 17K
|
Manufacturing
|
| O: -1.08%
H: 2.73%
C: -0.73%
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 0.31%
H: 0.68%
C: -0.8%
fda
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
Published: 2022-03-28 (Crawled : 23:00) - prnewswire.com
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 2.86%
H: 0.47%
C: -0.72%
ozempic fda control approval diabetes
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
Published: 2021-07-29 (Crawled : 21:00) - biospace.com/
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 0.49%
H: 0.26%
C: -0.62%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: 0.4%
H: 0.3%
C: -0.88%
ALNY | $147.495 -0.14% 110K
|
Health Technology
|
| O: -0.01%
H: 1.3%
C: -0.14%
new drug alcohol use disorder fda clearance treatment fda drug application clearance
BioCelerate Continues to Help Improve Nonclinical Study Operations through Public Private Partnership with the FDA
Published: 2021-06-07 (Crawled : 13:00) - biospace.com/
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: 0.59%
H: 0.59%
C: -0.28%
fda partnership
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
Published: 2021-05-27 (Crawled : 13:00) - biospace.com/
NVO | $123.58 -0.26% 2.2M
|
Health Technology
|
| O: -1.58%
H: 0.7%
C: -0.32%
LLY | $749.215 -0.21% 1.4M
|
Health Technology
|
| O: -0.17%
H: 0.36%
C: -0.72%
ALNY | $147.495 -0.14% 110K
|
Health Technology
|
| O: 0.57%
H: 1.91%
C: 0.46%
new drug fda fda acceptance drug application
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
WISA 4 | $7.86 349.14% 120M
|
Electronic Technology
TPET | $0.4951 114.24% 29M
|
n/a
JAGX | $0.1771 49.07% 540M
|
Health Technology
SXTC | $2.03 45.0% 27M
|
Health Technology
SPCB | $0.3888 40.87% 27M
|
Electronic Technology
DYNT | $0.52 40.39% 20M
|
Health Technology
SNGX | $0.54 39.86% 7.3M
|
Health Technology
BSGM | $1.53 39.09% 2.6M
|
Health Technology
MCBC | $13.74 38.37% 1.6M
|
Finance
PALI | $5.51 32.45% 28M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.